These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 36799235)
1. The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review. Reyburn R; Maher J; von Mollendorf C; Gwee A; Mulholland K; Russell F; J Glob Health; 2023 Feb; 13():05001. PubMed ID: 36799235 [TBL] [Abstract][Full Text] [Related]
2. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review. Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049 [No Abstract] [Full Text] [Related]
3. Effects of PCV10 and PCV13 on pneumococcal serotype 6C disease, carriage, and antimicrobial resistance. Grant LR; Hanquet G; Sepúlveda-Pachón IT; Theilacker C; Baay M; Slack MPE; Jodar L; Gessner BD Vaccine; 2024 Apr; 42(12):2983-2993. PubMed ID: 38553292 [TBL] [Abstract][Full Text] [Related]
4. Streptococcus pneumoniae as cause of acute otitis media (AOM) in Slovak children in the pneumococcal conjugate vaccine era (2008-2019). Macaj M; Perdochova L; Jakubikova J Vaccine; 2023 Jan; 41(2):452-459. PubMed ID: 36470684 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G; Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067 [TBL] [Abstract][Full Text] [Related]
6. Pneumococcal carriage in children in Ulaanbaatar, Mongolia before and one year after the introduction of the 13-valent pneumococcal conjugate vaccine. von Mollendorf C; Dunne EM; La Vincente S; Ulziibayar M; Suuri B; Luvsantseren D; Narangerel D; Ortika BD; Pell CL; Nation ML; Alamrousi A; Hinds J; Demberelsuren S; Nguyen C; Mungun T; Mulholland EK; Satzke C Vaccine; 2019 Jul; 37(30):4068-4075. PubMed ID: 31174939 [TBL] [Abstract][Full Text] [Related]
7. Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial. Orami T; Aho C; Ford RL; Pomat WS; Greenhill A; Kirkham LA; Masiria G; Nivio B; Britton KJ; Jacoby P; Richmond PC; van den Biggelaar AHJ; Lehmann D Vaccine; 2023 Aug; 41(37):5392-5399. PubMed ID: 37479616 [TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility and clonality of Streptococcus pneumoniae isolates recovered from invasive disease cases during a period with changes in pneumococcal childhood vaccination, Norway, 2004-2016. Siira L; Vestrheim DF; Winje BA; Caugant DA; Steens A Vaccine; 2020 Jul; 38(34):5454-5463. PubMed ID: 32616324 [TBL] [Abstract][Full Text] [Related]
9. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium. Wouters I; Desmet S; Van Heirstraeten L; Blaizot S; Verhaegen J; Van Damme P; Malhotra-Kumar S; Theeten H; Vaccine; 2019 Feb; 37(8):1080-1086. PubMed ID: 30665775 [TBL] [Abstract][Full Text] [Related]
10. Serotypes and antimicrobial resistance of León ME; Samudio M; Kawabata A; Nagai M; Rojas L; Zárate N; Irala J; Leguizamón M; Gómez G; Ortellado J; Blasco R; Franco R; Chamorro G J Med Microbiol; 2023 Jun; 72(6):. PubMed ID: 37289483 [No Abstract] [Full Text] [Related]
11. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine. Satzke C; Dunne EM; Choummanivong M; Ortika BD; Neal EFG; Pell CL; Nation ML; Fox KK; Nguyen CD; Gould KA; Hinds J; Chanthongthip A; Xeuatvongsa A; Mulholland EK; Sychareun V; Russell FM Vaccine; 2019 Jan; 37(2):296-305. PubMed ID: 30502068 [TBL] [Abstract][Full Text] [Related]
12. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV. Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581 [TBL] [Abstract][Full Text] [Related]
13. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil. Reis JN; Azevedo J; de Oliveira AML; Menezes APO; Pedrosa M; Dos Santos MS; Ribeiro LC; Freitas HF; Gouveia EL; Teles MB; Carvalho MDG; Reis MG; Nascimento-Carvalho C; Verani JR Vaccine; 2024 Jan; 42(3):591-597. PubMed ID: 38184393 [TBL] [Abstract][Full Text] [Related]
14. Systematic review on the impact of the pneumococcal conjugate vaccine ten valent (PCV10) or thirteen valent (PCV13) on all-cause, radiologically confirmed and severe pneumonia hospitalisation rates and pneumonia mortality in children 0-9 years old. Reyburn R; Tsatsaronis A; von Mollendorf C; Mulholland K; Russell FM; J Glob Health; 2023 Feb; 13():05002. PubMed ID: 36734192 [TBL] [Abstract][Full Text] [Related]
15. Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. Hanquet G; Krizova P; Dalby T; Ladhani SN; Nuorti JP; Danis K; Mereckiene J; Knol MJ; Winje BA; Ciruela P; de Miguel S; Portillo ME; MacDonald L; Morfeldt E; Kozakova J; Valentiner-Branth P; Fry NK; Rinta-Kokko H; Varon E; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Henriques-Normark B; Colzani E; Pastore-Celentano L; Savulescu C; Emerg Infect Dis; 2022 Jan; 28(1):137-138. PubMed ID: 34932457 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050 [TBL] [Abstract][Full Text] [Related]
17. High prevalence of antimicrobial resistance in non-vaccine serotypes of non-invasive/colonization isolates of Streptococcus pneumoniae: A cross-sectional study eight years after the licensure of conjugate vaccine in Japan. Kawaguchiya M; Urushibara N; Aung MS; Ito M; Takahashi A; Habadera S; Kobayashi N J Infect Public Health; 2020 Aug; 13(8):1094-1100. PubMed ID: 32446777 [TBL] [Abstract][Full Text] [Related]
18. Post-13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines. Ben-Shimol S; Givon-Lavi N; Kotler L; Adriaan van der Beek B; Greenberg D; Dagan R Emerg Infect Dis; 2021 Jan; 27(1):150-160. PubMed ID: 33350916 [TBL] [Abstract][Full Text] [Related]
19. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924 [TBL] [Abstract][Full Text] [Related]
20. Substantial reduction of antibiotic-non-susceptible pneumococcal otitis media following PCV7/PCV13 sequential introduction. Ben-Shimol S; Givon-Lavi N; Greenberg D; van der Beek BA; Leibovitz E; Dagan R J Antimicrob Chemother; 2020 Oct; 75(10):3038-3045. PubMed ID: 32946586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]